Hims & Hers Health is trading at €24.84, 6.19% down now amid continued investor concern over Visa’s monitoring program tied to customer payment disputes in its weight-loss subscription business.
- The company also faces FTC scrutiny over data-sharing, billing, and cancellation practices.
- Recent institutional buying from BNY Mellon provides support but has not offset compliance and margin concerns.
- Broader markets are largely flat, so the decline appears primarily company-specific.